Key Points
- Insider selling: REGENXBIO insider Steve Pakola sold 15,309 shares on May 11 at an average price of $11.02, totaling about $168,705. After the sale, he still held 232,617 shares, reducing his ownership by 6.17%.
- Recent earnings miss: The biotech company reported a quarterly loss of $1.72 per share, missing analyst expectations of a $1.34 loss, and revenue of $6.39 million versus the $25.84 million estimate.
- Mixed outlook from analysts: Wall Street currently has a Moderate Buy consensus on RGNX with an average price target of $27.50, despite some firms lowering ratings or price targets.
REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) insider Steve Pakola sold 15,309 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $11.02, for a total transaction of $168,705.18. Following the transaction, the insider directly owned 232,617 shares of the company's stock, valued at approximately $2,563,439.34. This trade represents a 6.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Steve Pakola also recently made the following trade(s):
- On Tuesday, March 10th, Steve Pakola sold 5,124 shares of REGENXBIO stock. The stock was sold at an average price of $10.35, for a total transaction of $53,033.40.
REGENXBIO Price Performance
Shares of RGNX opened at $10.04 on Thursday. The firm has a 50 day simple moving average of $8.97 and a 200-day simple moving average of $11.08. REGENXBIO Inc. has a 1-year low of $7.35 and a 1-year high of $16.19. The stock has a market cap of $518.23 million, a price-to-earnings ratio of -2.67 and a beta of 1.12.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.38). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The business had revenue of $6.39 million for the quarter, compared to analysts' expectations of $25.84 million. On average, equities analysts expect that REGENXBIO Inc. will post -2.88 earnings per share for the current fiscal year.
Institutional Trading of REGENXBIO
Hedge funds and other institutional investors have recently bought and sold shares of the company. State of Alaska Department of Revenue purchased a new stake in REGENXBIO in the 3rd quarter worth approximately $25,000. Aquatic Capital Management LLC purchased a new stake in REGENXBIO in the 3rd quarter worth approximately $37,000. Jones Financial Companies Lllp grew its stake in REGENXBIO by 44.4% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 1,270 shares during the period. Captrust Financial Advisors purchased a new stake in shares of REGENXBIO during the 2nd quarter valued at $85,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of REGENXBIO during the 4th quarter valued at $150,000. 88.08% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on RGNX shares. Morgan Stanley dropped their price objective on shares of REGENXBIO from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, March 5th. Wall Street Zen cut shares of REGENXBIO from a "hold" rating to a "sell" rating in a research note on Saturday, January 31st. Barclays initiated coverage on shares of REGENXBIO in a research note on Tuesday, January 27th. They issued an "overweight" rating and a $37.00 target price for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Finally, Robert W. Baird set a $27.00 target price on shares of REGENXBIO in a research note on Tuesday, February 10th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, REGENXBIO currently has an average rating of "Moderate Buy" and a consensus price target of $27.50.
Read Our Latest Research Report on REGENXBIO
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO's pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.
In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
